Cipla witnesses 3 senior-level exits including India biz CEO Nikhil Chopra

The company's rich legacy of care and strong sense of purpose rooted in a culture of meritocracy and high performance standards have made Cipla an employer of choice for several industry leaders

Cipla, Cipla logo, Cipla headquarters
Chopra joined the company in 1996 and has served in various leadership positions across India.
Press Trust of India New Delhi
2 min read Last Updated : Aug 04 2020 | 7:56 PM IST
Drug firm Cipla has witnessed three senior-level exits, including that of the company's Executive Vice-President and CEO for India business Nikhil Chopra.

The other two executives are Nikhil Lalwani, head of India prescription business, and Kunal Khanna, cluster head of chronic and emerging business development and portfolio.

"They have served significant tenures in Cipla; we deeply value their contribution, respect their professional aspirations and wish them all the best," Cipla said in a statement.

The company's rich legacy of care and strong sense of purpose rooted in a culture of meritocracy and high performance standards have made Cipla an employer of choice for several industry leaders, it added.

"Cipla is a professionally run organisation with robust talent management and succession development processes.

"Our business momentum continues to be on strong footing and we are backed by a solid workforce of 23,000 employees who are driving Cipla in its next growth phase," the statement said.

Chopra joined the company in 1996 and has served in various leadership positions across India.

The company, however, did not share the reasons for the exits.

Shares of Cipla closed at Rs 713.85 per scrip on the BSE, up 0.46 per cent from its previous close.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CiplaPharma industryPharma Companies

Next Story